Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04131036 · ClinicalTrials.gov registry record
Effects of Emicizumab vs. Factor VIII Prophylaxis on Joint and Bone Health in Severe Hemophilia A
A clinical trial of Hemophilia A, sponsored by Washington Institute for Coagulation.
- Recruiting
- Registry status
- 40
- Enrollment target
- 4
- Study locations
NCT04131036: Recruiting study of Hemophilia A, sponsored by Washington Institute for Coagulation.
NCT04131036 is a study of Hemophilia A that is actively recruiting participants, run by Washington Institute for Coagulation. The registered enrollment target is 40 participants, below the 91-participant average among 42 other Hemophilia A trials with a reported enrollment target (56% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04131036, a study of Hemophilia A, is actively recruiting participants, sponsored by Washington Institute for Coagulation.
- RECRUITING
- Registry status
- 40 participants
- Enrollment target
- 4
- Study locations
Study Summary
The investigators propose to study longitudinal joint and bone density changes in patients with severe Hemophilia A. Per current standard of care, most patients are on prophylactic FVIII replacement therapy intravenously several times weekly with a goal of keeping the trough \>1% FVIII. Recent phase 3 data suggest superior bleed protection with emicizumab prophylaxis every 1-2 weeks. It is the purpose of this study to longitudinally assess joint health and bone density over 3 years and to compare the effect of routine factor VIII prophylaxis with emicizumab prophylaxis.
Conditions Studied
Interventions
- OTHER assessment of joint health and bone density
Study Locations (4)
California
- Orthopedic Hemophilia Treatment Center - Los Angeles
- Hemophilia and Thrombosis Treatment Center, University of California, San Diego - San Diego
Texas
- The University of Texas Health Science Center at San Antonio - San Antonio
Washington
- Washington Center for Bleeding Disorders at Washington Institute for Coagulation - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2019-04-04 |
| Est. Completion | 2026-08 |
What NCT04131036 shows while recruiting
NCT04131036 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 91-participant average among 42 other Hemophilia A trials with a reported enrollment target (56% lower).
The record links to 1 condition, with Hemophilia A appearing as the primary indexed condition, and to 1 intervention - of which assessment of joint health and bone density is the first listed.
NCT04131036 reports a single indexed study location in California, Texas, Washington.
Frequently Asked Questions
What is clinical trial NCT04131036 about?
NCT04131036 is a clinical study titled "Effects of Emicizumab vs. Factor VIII Prophylaxis on Joint and Bone Health in Severe Hemophilia A". The investigators propose to study longitudinal joint and bone density changes in patients with severe Hemophilia A. Per current standard of care, most patients are on prophylactic FVIII replacement therapy intravenously several times weekly with a goal of keeping the trough \>1% FVIII. Recent phase...
What is the current status of trial NCT04131036?
This trial is currently recruiting. The enrollment target is 40 participants. The study started on 2019-04-04. Estimated completion is 2026-08.
What conditions does trial NCT04131036 study?
This clinical trial studies the following conditions: Hemophilia A.
What interventions are being tested in trial NCT04131036?
The interventions under investigation include: assessment of joint health and bone density (OTHER).
Who is sponsoring clinical trial NCT04131036?
This trial is sponsored by Washington Institute for Coagulation, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04131036 being conducted?
This trial has 4 study locations across California, Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hemophilia A
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04131036's enrollment target sits among peer trials
40 23rd of 42 higher than 20 of 42 other Hemophilia A trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hemophilia A trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
RECRUITING · Phase 3
-
Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
RECRUITING · Phase 3
-
A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A
RECRUITING · Phase 1
-
Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for Surgery
RECRUITING · Phase 4
-
Hemophilia A Research Program
RECRUITING
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI